Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented November 5, 2024
First Patient Dosed in Ph 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma October 29, 2024
Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma Presented October 29, 2024
Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced October 15, 2024
Key Progress and Upcoming Studies for Pelareorep Breast and Pancreatic Cancer Treatments Announced in Preparation for FDA Accelerated Approval Path October 8, 2024
Significant New Data from Ph 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer Announced October 1, 2024
Positive Preliminary Data Reported in Ph 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer September 24, 2024
Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement for Ph 1/2a Study of SON-1210 + Chemo for the Treatment of Pancreatic Cancer August 22, 2024
FDA Clears IND Application for Ph 1b Study of PTM-101 for the Localized Treatment of Pancreatic Cancer August 22, 2024
FAILED TRIAL: Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies show primary endpoint of OS improvement not achieved August 6, 2024
FDA grants Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer August 6, 2024
RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study July 23, 2024
Application filed for for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer July 17, 2024
Third Independent Safety Review of Ph 3 ASPIRE Clinical Trial Announced; DSMB Recommended Continuation with No Trial Modification July 1, 2024
Substantial OS Benefit and Unprecedented DoR in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1L Pancreatic Cancer Announced July 1, 2024
Data from 1-BETTER Ph 1/2 study for advanced pancreatic cancer of Natrunix + ONIVYDE/5-FU announced June 25, 2024
Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer June 18, 2024
